<p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX - 獲取免費報告）的股票在目前覆蓋該公司的十三家評級機構中獲得了 “適度買入” 的平均推薦，MarketBeat.com 報道稱。一位分析師對該股票給予了賣出評級，兩位給予了持有評級，十位則對該公司給予了買入評級。在過去一年中，更新了對該股票覆蓋的分析師的平均一年價格目標為 48.9167 美元。</p>
<ul>
<li>3 家不為人知的醫療保健公司</li>
</ul>
<p>一些股票研究分析師最近對 TVTX 股票發佈了報告。TD Cowen 將 Travere Therapeutics 的股票目標價從 45.00 美元上調至 60.00 美元，並在 5 月 5 日的研究報告中給予該公司 “買入” 評級。Wedbush 在 6 月 3 日的研究報告中重申了 “跑贏大盤” 評級，並對 Travere Therapeutics 的股票設定了 55.00 美元的目標價。花旗集團在週三將 Travere Therapeutics 的股票目標價從 59.00 美元上調至 62.00 美元，並給予該公司 “買入” 評級。Piper Sandler 在 4 月 14 日的研究報告中將 Travere Therapeutics 的股票評級從 “中性” 上調至 “增持”，並設定了 49.00 美元的目標價。最後，HC Wainwright 在 6 月 2 日的研究報告中將 Travere Therapeutics 的股票目標價從 57.00 美元上調至 67.00 美元，並給予該公司 “買入” 評級。</p>
<p>獲取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<p><strong>查看我們關於 TVTX 的最新報告</strong></p>
<h2>內部人士下注</h2>
<ul>
<li>Travere Therapeutics 在鼓舞人心的數據後仍在上升</li>
</ul>
<p>在其他新聞中，首席執行官 Eric M. Dube 在 5 月 6 日的交易中出售了 22,500 股公司的股票。這些股票以平均價格 43.95 美元出售，總價值為 988,875.00 美元。出售後，首席執行官直接持有 432,886 股公司的股票，價值約為 19,025,339.70 美元。此次交易使其持股減少了 4.94%。該交易已在與證券交易委員會的法律文件中披露，文件可在此鏈接查看。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，內部人士 William E. Rote 在 5 月 6 日的交易中出售了 2,763 股公司的股票。這些股票以平均價格 43.95 美元出售，總交易額為 121,433.85 美元。出售完成後，該內部人士直接持有 115,474 股公司的股票，價值為 5,075,082.30 美元。這筆交易代表其持股減少了 2.34%。該銷售的 SEC 文件提供了更多信息。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去的九十天裏，內部人士出售了價值 15,895,428 美元的 400,015 股公司股票。內部人士持有公司股票的 4.44%。</p>
<h2>機構投資者對 Travere Therapeutics 的看法</h2>
<p>幾家大型投資者最近增加或減少了對該公司的持股。加利福尼亞州教師退休系統在第一季度將其在 Travere Therapeutics 的持股增加了 32.3%。加利福尼亞州教師退休系統現在擁有 105,132 股公司股票，價值 3,123,000 美元，在此期間又購買了 25,660 股。Elmind Capital LP 在第一季度將其在 Travere Therapeutics 的持股增加了 61.5%。Elmind Capital LP 現在擁有 177,600 股公司股票，價值 5,276,000 美元，在此期間又購買了 67,600 股。Empowered Funds LLC 在第一季度將其在 Travere Therapeutics 的持股增加了 2,719.8%。Empowered Funds LLC 現在擁有 84,820 股公司股票，價值 2,520,000 美元，在此期間又購買了 81,812 股。Quantinno Capital Management LP 在第一季度將其在 Travere Therapeutics 的持股增加了 354.4%。Quantinno Capital Management LP 現在擁有 68,317 股公司股票，價值 2,030,000 美元，在此期間又購買了 53,283 股。最後，Rice Hall James &amp; Associates LLC 在第一季度將其在 Travere Therapeutics 的持股增加了 1.3%。Rice Hall James &amp; Associates LLC 現在擁有 92,757 股公司股票，價值 2,756,000 美元，在此期間又購買了 1,221 股。</p>
<h2>Travere Therapeutics 股票表現</h2>
<p>納斯達克：TVTX 週一開盤價為 45.81 美元。該公司的債務與股本比率為 3.16，流動比率為 3.13，速動比率為 3.08。該公司的市值為 42.6 億美元，市盈率為-199.17，貝塔值為 1.13。該公司的 50 日移動平均線為 39.71 美元，200 日移動平均線為 34.79 美元。Travere Therapeutics 的 1 年最低價為 13.88 美元，1 年最高價為 48.61 美元。</p>
<p>Travere Therapeutics（納斯達克代碼：TVTX - 獲取免費報告）最後一次發佈季度財報是在 5 月 4 日。該公司報告每股收益（EPS）為 0.05 美元，超出分析師的共識預期（-0.24 美元）0.29 美元。該公司本季度的收入為 1.272 億美元，而共識預期為 1.3623 億美元。Travere Therapeutics 的淨利潤率為-4.00%，股本回報率為-26.16%。該公司的收入同比增長 55.6%。在去年同期，該公司每股收益為-0.47 美元。分析師預測 Travere Therapeutics 在本年度將發佈-0.29 美元的每股收益。</p>
<h2>關於 Travere Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Travere Therapeutics, Inc NASDAQ: TVTX 是一家總部位於加利福尼亞州聖地亞哥的生物製藥公司，致力於開發和商業化針對罕見腎臟和遺傳疾病的療法。公司的使命是通過關注影響小患者羣體的疾病，解決治療選擇有限的未滿足需求。Travere 結合了研究、開發和商業能力，將創新藥物推向市場。</p>
<p>公司的主要產品是 sparsentan，一種雙重內皮素 - 血管緊張素受體拮抗劑，已獲得美國的加速批准。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Travere Therapeutics</li>
<li>這三隻保險股創下 52 周新高：還有買入的機會嗎？</li>
<li>三隻股價低於 20 美元的股票，值得在更廣泛的市場反彈前買入</li>
<li>Petco 面臨激烈競爭，但勢頭正在增強</li>
<li>鎖定效應是真實存在的——這三家房屋建築商正在押注於此</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Travere Therapeutics 嗎？</h2>
<p>在考慮 Travere Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在買入的股票，而 Travere Therapeutics 並不在名單上。</p>
<p>雖然 Travere Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>在這裏查看這五隻股票</p>

TVTX

<p>Travere Therapeutics（納斯達克代碼：TVTX）獲得了 13 位分析師的 “適度買入” 共識，1 年期平均目標價為 48.92 美元。最近的升級包括 TD Cowen 將其目標價上調至 60 美元，花旗集團上調至 62 美元。同時，首席執行官 Eric M. Dube 和內部人士 William E. Rote 在 5 月份根據 10b5-1 規則出售了股份。相反，包括加利福尼亞州教師退休系統和 Elmind Capital LP 在內的幾家機構投資者在第一季度顯著增加了他們的持股</p>

<p>Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have received an average recommendation of &#34;Moderate Buy&#34; from the thirteen ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $48.9167.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX - 獲取免費報告）的股票在目前覆蓋該公司的十三家評級機構中獲得了 “適度買入” 的平均推薦，MarketBeat.com 報道稱。一位分析師對該股票給予了賣出評級，兩位給予了持有評級，十位則對該公司給予了買入評級。在過去一年中，更新了對該股票覆蓋的分析師的平均一年價格目標為 48.9167 美元。</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不為人知的醫療保健公司</li>
</ul>
</div><p>A number of equities research analysts have recently issued reports on TVTX shares. TD Cowen boosted their price target on shares of Travere Therapeutics from $45.00 to $60.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, May 5th. Wedbush reissued an &#34;outperform&#34; rating and issued a $55.00 price target on shares of Travere Therapeutics in a research note on Wednesday, June 3rd. Citigroup boosted their price target on shares of Travere Therapeutics from $59.00 to $62.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday. Piper Sandler raised shares of Travere Therapeutics from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and set a $49.00 price target on the stock in a research note on Tuesday, April 14th. Finally, HC Wainwright boosted their price target on shares of Travere Therapeutics from $57.00 to $67.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, June 2nd.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對 TVTX 股票發佈了報告。TD Cowen 將 Travere Therapeutics 的股票目標價從 45.00 美元上調至 60.00 美元，並在 5 月 5 日的研究報告中給予該公司 “買入” 評級。Wedbush 在 6 月 3 日的研究報告中重申了 “跑贏大盤” 評級，並對 Travere Therapeutics 的股票設定了 55.00 美元的目標價。花旗集團在週三將 Travere Therapeutics 的股票目標價從 59.00 美元上調至 62.00 美元，並給予該公司 “買入” 評級。Piper Sandler 在 4 月 14 日的研究報告中將 Travere Therapeutics 的股票評級從 “中性” 上調至 “增持”，並設定了 49.00 美元的目標價。最後，HC Wainwright 在 6 月 2 日的研究報告中將 Travere Therapeutics 的股票目標價從 57.00 美元上調至 67.00 美元，並給予該公司 “買入” 評級。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Report on TVTX</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 TVTX 的最新報告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>Travere Therapeutics 在鼓舞人心的數據後仍在上升</li>
</ul>
</div><p>In other news, CEO Eric M. Dube sold 22,500 shares of the business's stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total value of $988,875.00. Following the sale, the chief executive officer directly owned 432,886 shares of the company's stock, valued at approximately $19,025,339.70. The trade was a 4.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William E. Rote sold 2,763 shares of the business's stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total transaction of $121,433.85. Following the completion of the sale, the insider directly owned 115,474 shares in the company, valued at $5,075,082.30. This trade represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 400,015 shares of company stock worth $15,895,428. Insiders own 4.44% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席執行官 Eric M. Dube 在 5 月 6 日的交易中出售了 22,500 股公司的股票。這些股票以平均價格 43.95 美元出售，總價值為 988,875.00 美元。出售後，首席執行官直接持有 432,886 股公司的股票，價值約為 19,025,339.70 美元。此次交易使其持股減少了 4.94%。該交易已在與證券交易委員會的法律文件中披露，文件可在此鏈接查看。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，內部人士 William E. Rote 在 5 月 6 日的交易中出售了 2,763 股公司的股票。這些股票以平均價格 43.95 美元出售，總交易額為 121,433.85 美元。出售完成後，該內部人士直接持有 115,474 股公司的股票，價值為 5,075,082.30 美元。這筆交易代表其持股減少了 2.34%。該銷售的 SEC 文件提供了更多信息。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去的九十天裏，內部人士出售了價值 15,895,428 美元的 400,015 股公司股票。內部人士持有公司股票的 4.44%。</p>
</div><h2>Institutional Investors Weigh In On Travere Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Travere Therapeutics 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its stake in Travere Therapeutics by 32.3% during the 1st quarter. California State Teachers Retirement System now owns 105,132 shares of the company's stock worth $3,123,000 after buying an additional 25,660 shares during the period. Elmind Capital LP increased its stake in Travere Therapeutics by 61.5% during the 1st quarter. Elmind Capital LP now owns 177,600 shares of the company's stock worth $5,276,000 after buying an additional 67,600 shares during the period. Empowered Funds LLC increased its stake in Travere Therapeutics by 2,719.8% during the 1st quarter. Empowered Funds LLC now owns 84,820 shares of the company's stock worth $2,520,000 after buying an additional 81,812 shares during the period. Quantinno Capital Management LP increased its stake in Travere Therapeutics by 354.4% during the 1st quarter. Quantinno Capital Management LP now owns 68,317 shares of the company's stock worth $2,030,000 after buying an additional 53,283 shares during the period. Finally, Rice Hall James &amp; Associates LLC increased its stake in Travere Therapeutics by 1.3% during the 1st quarter. Rice Hall James &amp; Associates LLC now owns 92,757 shares of the company's stock worth $2,756,000 after buying an additional 1,221 shares during the period.</p>
<div class="lb-trans"><p>幾家大型投資者最近增加或減少了對該公司的持股。加利福尼亞州教師退休系統在第一季度將其在 Travere Therapeutics 的持股增加了 32.3%。加利福尼亞州教師退休系統現在擁有 105,132 股公司股票，價值 3,123,000 美元，在此期間又購買了 25,660 股。Elmind Capital LP 在第一季度將其在 Travere Therapeutics 的持股增加了 61.5%。Elmind Capital LP 現在擁有 177,600 股公司股票，價值 5,276,000 美元，在此期間又購買了 67,600 股。Empowered Funds LLC 在第一季度將其在 Travere Therapeutics 的持股增加了 2,719.8%。Empowered Funds LLC 現在擁有 84,820 股公司股票，價值 2,520,000 美元，在此期間又購買了 81,812 股。Quantinno Capital Management LP 在第一季度將其在 Travere Therapeutics 的持股增加了 354.4%。Quantinno Capital Management LP 現在擁有 68,317 股公司股票，價值 2,030,000 美元，在此期間又購買了 53,283 股。最後，Rice Hall James &amp; Associates LLC 在第一季度將其在 Travere Therapeutics 的持股增加了 1.3%。Rice Hall James &amp; Associates LLC 現在擁有 92,757 股公司股票，價值 2,756,000 美元，在此期間又購買了 1,221 股。</p>
</div><h2>Travere Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Travere Therapeutics 股票表現</h2>
</div><p>NASDAQ:TVTX opened at $45.81 on Monday. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 3.08. The firm has a market capitalization of $4.26 billion, a price-to-earnings ratio of -199.17 and a beta of 1.13. The company's 50-day moving average is $39.71 and its two-hundred day moving average is $34.79. Travere Therapeutics has a 1-year low of $13.88 and a 1-year high of $48.61.</p>
<div class="lb-trans"><p>納斯達克：TVTX 週一開盤價為 45.81 美元。該公司的債務與股本比率為 3.16，流動比率為 3.13，速動比率為 3.08。該公司的市值為 42.6 億美元，市盈率為-199.17，貝塔值為 1.13。該公司的 50 日移動平均線為 39.71 美元，200 日移動平均線為 34.79 美元。Travere Therapeutics 的 1 年最低價為 13.88 美元，1 年最高價為 48.61 美元。</p>
</div><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million for the quarter, compared to the consensus estimate of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business's revenue was up 55.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.47) EPS. Analysts forecast that Travere Therapeutics will post -0.29 EPS for the current year.</p>
<div class="lb-trans"><p>Travere Therapeutics（納斯達克代碼：TVTX - 獲取免費報告）最後一次發佈季度財報是在 5 月 4 日。該公司報告每股收益（EPS）為 0.05 美元，超出分析師的共識預期（-0.24 美元）0.29 美元。該公司本季度的收入為 1.272 億美元，而共識預期為 1.3623 億美元。Travere Therapeutics 的淨利潤率為-4.00%，股本回報率為-26.16%。該公司的收入同比增長 55.6%。在去年同期，該公司每股收益為-0.47 美元。分析師預測 Travere Therapeutics 在本年度將發佈-0.29 美元的每股收益。</p>
</div><h2>About Travere Therapeutics</h2>
<div class="lb-trans"><h2>關於 Travere Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc NASDAQ: TVTX 是一家總部位於加利福尼亞州聖地亞哥的生物製藥公司，致力於開發和商業化針對罕見腎臟和遺傳疾病的療法。公司的使命是通過關注影響小患者羣體的疾病，解決治療選擇有限的未滿足需求。Travere 結合了研究、開發和商業能力，將創新藥物推向市場。</p>
</div><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>公司的主要產品是 sparsentan，一種雙重內皮素 - 血管緊張素受體拮抗劑，已獲得美國的加速批准。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?</li>
<li>3 Stocks Under $20 to Buy Before a Broader Market Rally</li>
<li>Petco Faces Tough Competition, But Momentum Is Building</li>
<li>The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Travere Therapeutics</li>
<li>這三隻保險股創下 52 周新高：還有買入的機會嗎？</li>
<li>三隻股價低於 20 美元的股票，值得在更廣泛的市場反彈前買入</li>
<li>Petco 面臨激烈競爭，但勢頭正在增強</li>
<li>鎖定效應是真實存在的——這三家房屋建築商正在押注於此</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Travere Therapeutics 嗎？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Travere Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在買入的股票，而 Travere Therapeutics 並不在名單上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Travere Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by Brokerages

Market Beat

Travere Therapeutics, Inc.（納斯達克股票代碼：TVTX）被券商一致評為 “適度買入”